Cagrilintide and semaglutide act on two different hormonal pathways, and that difference is the whole reason they get studied together. Semaglutide targets the glucagon-like peptide-1 (GLP-1) receptor, a mechanism already present in several approved medications. Cagrilintide acts on amylin receptors, a separate pathway tied to a different satiety signal. Researchers have looked at what happens when both pathways are engaged at once. That combination is called CagriSema, and the findings have drawn a lot of attention in the metabolic-medicine literature.
How Each Compound Works
Semaglutide is a synthetic analogue of GLP-1, a hormone the gut secretes after meals. It binds to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract. Research reports that GLP-1 receptor activation slows gastric emptying, promotes insulin secretion in a glucose-dependent manner, and reduces appetite signaling in the hypothalamus. Its chemical structure is modified to extend the half-life to roughly seven days, which allows once-weekly subcutaneous dosing in approved pharmaceutical formulations. Regulators (FDA, EMA) have approved it for glycemic management in type 2 diabetes and for chronic weight management under specific brand names.
Cagrilintide is a long-acting amylin analogue. Amylin is a peptide co-secreted with insulin from pancreatic beta cells. It acts on area postrema receptors in the brainstem and is understood to complement insulin by slowing gastric emptying and signaling satiety. Native amylin has a very short half-life, which limits its usefulness. Cagrilintide is engineered with fatty-acid (lipidation) conjugation to extend its duration of action. A 2021 paper in the Journal of Medicinal Chemistry describing its development reports a half-life on the order of 159–195 hours, consistent with a once-weekly dosing profile. In the current literature, cagrilintide is an investigational compound, not approved for human therapeutic use, and is studied in clinical trial settings under sponsor oversight.
The CagriSema Combination
GLP-1 and amylin receptors work through distinct but complementary mechanisms. That led researchers to hypothesize that combining them could engage additive satiety pathways. CagriSema is a fixed-ratio co-formulation of cagrilintide and semaglutide being developed by Novo Nordisk. Phase 2 and Phase 3 trial data have appeared in the peer-reviewed literature and at major endocrinology conferences. Research reports that the combination produced greater mean weight reduction than either compound alone in trial participants, though results have varied across studies and populations.
The Phase 3 REDEFINE 1 trial (3,417 adults with obesity or overweight without type 2 diabetes) was published in The New England Journal of Medicine in 2025. Per Novo Nordisk's reporting of that trial, CagriSema 2.4 mg/2.4 mg produced a mean weight reduction of about 22.7% at 68 weeks under one analysis, compared with semaglutide alone, cagrilintide alone, and placebo. In a separate head-to-head trial, REDEFINE 4, Novo Nordisk reported in early 2026 that CagriSema produced roughly 23% weight reduction but did not meet its primary endpoint of non-inferiority to tirzepatide. Novo Nordisk announced in December 2025 that it had filed for FDA approval of CagriSema for chronic weight management. As of mid-2026 no regulatory approval has been granted. It remains an investigational therapy under review.
Side-by-Side Summary
| Feature | Semaglutide | Cagrilintide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Amylin receptor agonist |
| Natural analogue | GLP-1 (gut-derived) | Amylin (pancreatic) |
| Half-life (approx.) | ~7 days | ~159–195 hours (reported) |
| Regulatory status | FDA/EMA approved (specific indications) | Investigational; not approved |
| Dosing frequency (studied) | Once weekly | Once weekly (in trials) |
| Primary research signals | Appetite, gastric emptying, insulin secretion | Satiety, gastric emptying (brainstem pathway) |
| Combination context | Component of CagriSema | Component of CagriSema |
Research Context and Caveats
The gap between approved and investigational status matters in practice. Semaglutide is sold as licensed pharmaceutical products made to established quality standards. Cagrilintide is not. It is not approved for human use and is sold by research-chemical suppliers for laboratory use only, which puts it outside the regulatory framework that governs pharmaceutical manufacturing, purity verification, and clinical monitoring. Material marketed to the research market is not approved for human consumption.
Independent testing services indexed by aggregators such as Finnrick, and analytical laboratories such as Janoshik, have analyzed research-market peptide samples for purity and identity using methods including HPLC and mass spectrometry. Reported results vary substantially across suppliers and batches, which is why third-party certificate-of-analysis data matters for any research-context procurement decision.
The science around amylin–GLP-1 co-agonism is still active. Additional Phase 3 data for CagriSema is expected to inform whether and how a combination product reaches regulators. Until regulatory review concludes, every outcome reported in the literature represents a trial-context finding, not an established therapeutic benchmark. None of the above is medical advice.
Sources
- pubmed.ncbi.nlm.nih.gov — peer-reviewed literature on GLP-1 receptor agonists and amylin analogues
- nejm.org — New England Journal of Medicine, publisher of the REDEFINE 1 CagriSema trial (2025)
- novonordisk.com — sponsor announcements on CagriSema trials (REDEFINE 1, REDEFINE 4) and the December 2025 FDA filing
- ema.europa.eu — European Medicines Agency product information for approved semaglutide formulations
- fda.gov — FDA approvals and trial registry information
- finnrick.com — aggregator of independent peptide purity and identity testing data
- janoshik.com — independent analytical laboratory reports for research-market compounds